Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX +5.61%26 Net Cash per Share is $3.77 as of Jun. 2026. GuruFocus rates BJDX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 296 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 99.66% on this metric.
The historical rank and industry rank for Bluejay Diagnostics's Net Cash per Share or its related term are showing as below:
BJDX'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.11 Med: 1.49 Max: 8.31
Current: 0.13
During the past 7 years, the highest Price-to-Net-Cash Ratio of Bluejay Diagnostics was 8.31. The lowest was 0.11. And the median was 1.49.
BJDX's Price-to-Net-Cash is ranked better than 99.66% of 296
companies
in the Medical Devices & Instruments industry
Industry Median: 9.625
vs BJDX: 0.13
Bluejay Diagnostics (NAS:BJDX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Bluejay Diagnostics Net Cash per Share Related Terms
Bluejay Diagnostics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs ODYY, VTAK, ESMC: Net Cash per Share Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's Price-to-Net-Cash falls into.
Bluejay Diagnostics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Bluejay Diagnostics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a Net Cash per Share of $3.77 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bluejay Diagnostics and its competitors. According to the industry distribution chart, Bluejay Diagnostics ranks #1 out of 296 companies in the Medical Devices & Instruments industry, placing it in the top 0.3%.
Is Bluejay Diagnostics' Net Cash per Share too high?
Bluejay Diagnostics' current Net Cash per Share is $3.77. The Medical Devices & Instruments industry median Net Cash per Share is 9.63. Bluejay Diagnostics' value of $3.77 is 60.8% below this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #1 out of 296 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Net Cash per Share compare to ODYY and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #1 out of 296 companies for Net Cash per Share. This places Bluejay Diagnostics in the top 0% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 9.63. Bluejay Diagnostics' value of $3.77 is 60.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.63, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current Net Cash per Share of $3.77 is 60.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current Net Cash per Share is $3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Net Cash per Share of $3.77. The current Net Cash per Share is $3.77 and 60.8% below the Medical Devices & Instruments industry median of 9.63. Bluejay Diagnostics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Net Cash per Share is $3.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc. is a medical diagnostics company based in the United States that develops near-patient testing systems intended to improve patient outcomes. Its primary platform is the Symphony System, a rapid, cost-effective testing device designed for use in sepsis triage and monitoring of disease progression. The company's lead product candidate is an IL-6 Test for sepsis, which is designed to deliver accurate results in approximately 20 minutes from sample to result, helping medical professionals make earlier triage and treatment decisions. Bluejay targets hospitals, clinics, and other healthcare providers that require fast diagnostic information at or near the point of care. Its revenue model is expected to be based on sales of the Symphony System instruments and recurring sales of proprietary test cartridges and related consumables. The company is headquartered in the United States and focuses primarily on the domestic healthcare market.
26GF Score
Get the complete analysis for BJDX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
